Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative b-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ 2017 June 20. [Epub ahead of print] - PAI - Policy Analysis Inc.

Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative b-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ 2017 June 20. [Epub ahead of print] - PAI - Policy Analysis Inc.